The FDA has approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are inadequately controlled with H1 antihistamines.
Rhapsido is the first treatment approved for symptomatic dermographism, according to an Oct. 7 news release. The oral selective BTK inhibitor is also the only prescription treatment approved for both chronic spontaneous urticaria and symptomatic dermographism when antihistamines fail.
The approval was supported by the phase 3 REMODEL-1 and REMODEL-2 studies. At week 12, 29.3% of patients receiving Rhapsido achieved the study’s measured response compared with 14% receiving placebo.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
